Constructing immune and prognostic features associated with ADCP in hepatocellular carcinoma and pan-cancer based on scRNA-seq and bulk RNA-seq

• Published in: Frontiers in immunology Vol. 15; p. 1397541
• Main Authors: Zhang, Zhengwei, Li, Yuying, Quan, Zhen, Li, Yapeng, Zhu, Liying, Sun, Shibo, Chen, Xiaoning
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 07.05.2024
• Subjects: antibody-dependent cellular phagocytosis; Biomarkers, Tumor - genetics; Carcinoma, Hepatocellular - genetics; Carcinoma, Hepatocellular - immunology; Carcinoma, Hepatocellular - therapy; Claudins - genetics; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; hepatocellular carcinoma; Humans; immunity; Immunology; Immunotherapy - methods; Liver Neoplasms - genetics; Liver Neoplasms - immunology; Liver Neoplasms - therapy; Male; pan-cancer; Phagocytosis - genetics; Prognosis; RNA-Seq; Single-Cell Gene Expression Analysis; Tumor Microenvironment - genetics; Tumor Microenvironment - immunology; pan-cancer; immunity; antibody-dependent cellular phagocytosis; prognosis; hepatocellular carcinoma
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2024.1397541

Despite the significant therapeutic outcomes achieved in systemic treatments for liver hepatocellular carcinoma (LIHC), it is an objective reality that only a low proportion of patients exhibit an improved objective response rate (ORR) to current immunotherapies. Antibody-dependent cellular phagocytosis (ADCP) immunotherapy is considered the new engine for precision immunotherapy. Based on this, we aim to develop an ADCP-based LIHC risk stratification system and screen for relevant targets. Utilizing a combination of single-cell RNA sequencing (scRNA-seq) and bulk RNA-seq data, we screened for ADCP modulating factors in LIHC and identified differentially expressed genes along with their involved functional pathways. A risk scoring model was established by identifying ADCP-related genes with prognostic value through LASSO Cox regression analysis. The risk scoring model was then subjected to evaluations of immune infiltration and immunotherapy relevance, with pan-cancer analysis and experimental studies conducted on key targets. Building on the research by Kamber RA et al., we identified GYPA, CLDN18, and IRX5 as potential key target genes regulating ADCP in LIHC. These genes demonstrated significant correlations with immune infiltration cells, such as M1-type macrophages, and the effectiveness of immunotherapy in LIHC, as well as a close association with clinical pathological staging and patient prognosis. Pan-cancer analysis revealed that CLDN18 was prognostically and immunologically relevant across multiple types of cancer. Validation through tissue and cell samples confirmed that GYPA and CLDN18 were upregulated in liver cancer tissues and cells. Furthermore, knockdown of CLDN18 inhibited the malignancy capabilities of liver cancer cells. We have identified an ADCP signature in LIHC comprising three genes. Analysis based on a risk scoring model derived from these three genes, coupled with subsequent experimental validation, confirmed the pivotal role of M1-type macrophages in ADCP within LIHC, establishing CLDN18 as a critical ADCP regulatory target in LIHC.